SILO PHARMA INC. - COMMON STOCK

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

22 يناير 2025 07:29:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

08 يناير 2025 07:29:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

02 يناير 2025 07:45:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

18 ديسمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

29 نوفمبر 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

18 نوفمبر 2024 07:40:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

31 أكتوبر 2024 07:35:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

10 سبتمبر 2024 05:35:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

14 أغسطس 2024 13:30:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

07 أغسطس 2024 07:13:00 بحسب Nasdaq GlobeNewswire

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

26 يوليو 2024 07:20:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

22 يوليو 2024 15:45:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

19 يوليو 2024 07:01:00 بحسب Nasdaq GlobeNewswire

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

18 يوليو 2024 07:25:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

16 يوليو 2024 05:30:00 بحسب Nasdaq GlobeNewswire

IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

30 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire